Staying Fit
Don’t Let the Flu Hold You Back
Take this short quiz and be better prepared
AARP Advertiser
Every adult 65 and older should take the flu seriously, but especially those with underlying conditions such as chronic lung disease (asthma or COPD) and heart disease, and those with compromised immune systems. For those adults, the flu can lead to further flu-related complications. Complete this short true or false quiz and earn 450 Rewards Points and be better prepared for flu season.
Don’t Let the Flu Hold You Back
Don’t Let the Flu Hold You Back
What is FLUZONE® HIGH-DOSE QUADRIVALENT (INFLUENZA VACCINE)?
Fluzone High-Dose Quadrivalent is a vaccine that helps protect against influenza illness (flu). Fluzone High-Dose Quadrivalent vaccine is for people 65 years of age and older. Click for Flu Shot Locator Tool.
IMPORTANT SAFETY INFORMATION
Fluzone High-Dose Quadrivalent should not be given to anyone who has had a severe allergic reaction to any component of the vaccine, including eggs or egg products, or after previous dose of any influenza vaccine.
Tell your health care provider if you have ever had Guillain-Barré syndrome (severe muscle weakness) after a previous influenza vaccination.
If Fluzone High-Dose Quadrivalent is given to people with a compromised immune system, including those receiving therapies that suppress the immune system, the immune response may be lower than expected.
Vaccination with Fluzone High-Dose Quadrivalent may not protect all people who receive the vaccine.
For Fluzone High-Dose Quadrivalent, in adults 65 years of age and older, the most common side effects were pain, redness and/or swelling where you got the shot; muscle ache, headache, and general discomfort. Other side effects may occur.|
For more information, talk to your health care professional and refer to the full Prescribing Information for Fluzone High-Dose Quadrivalent. Also, please see complete Patient Information for Fluzone High-Dose Quadrivalent.
© 2023 Sanofi Pasteur Inc. All rights reserved. For US Residents Only.
MAT-US-2305230-v1.0-08/2023
ADVERTISEMENT
ADVERTISEMENT